BioSig Technologies, Inc. (BSGM): Price and Financial Metrics
GET POWR RATINGS... FREE!
BSGM Stock Price Chart Interactive Chart >
BSGM Price/Volume Stats
| Current price | $3.68 | 52-week high | $11.09 |
| Prev. close | $3.82 | 52-week low | $2.79 |
| Day low | $3.63 | Volume | 282,900 |
| Day high | $4.00 | Avg. volume | 284,409 |
| 50-day MA | $3.65 | Dividend yield | N/A |
| 200-day MA | $4.53 | Market Cap | 118.42M |
BioSig Technologies, Inc. (BSGM) Company Bio
BioSig Technologies, Inc., a medical device company, engages in developing and commercializing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. The company's proprietary product include precise uninterrupted real-time evaluation of electrograms electrophysiology system, a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures in an electrophysiology laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases. BioSig Technologies, Inc. was founded in 2009 and is headquartered in Westport, Connecticut.
Latest BSGM News From Around the Web
Below are the latest news stories about BioSig Technologies Inc that investors may wish to consider to help them evaluate BSGM as an investment opportunity.
Where Do Hedge Funds Stand On BioSig Technologies, Inc. (BSGM)?At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of March 31st. In this […] |
BioSig Technologies, Inc. to Present New Clinical Data at Heart Rhythm 2021 Annual ConventionCompany’s conference program to include physician presentations and new technology demonstrations for its proprietary signal processing system for arrhythmia careWestport, CT, June 15, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company woul |
BioSig Technologies, Inc. to Present at the LD Micro Invitational XI Virtual EventPresentation on Tuesday, June 8, 2021, at 5 PM ETWestport, CT, June 07, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc. would be presenting at the upcoming LD Micro Invitational |
BioSig Technologies, Inc. to Present at the Jefferies Virtual Healthcare ConferenceWestport, CT, May 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc. would be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021, at 2 pm ET. BioSig’s PURE EP(tm) System is an advanced signal acquisition and processing platform that aims to drive procedural efficiency and efficacy in electrophysiology. The system provides essential diagnostic signals with high clinical value in all types of cardiac ablations that treat irregular heartbea... |
BioSig Sees Increased Case Volume from Expanding Base of Medical Centers Using Its Proprietary Signal Processing SystemThe Company sees increased technology usage across its installed base and anticipates enrolling to at least 1500 cases by the end of 2021 44 physicians have conducted over 800 arrhythmia patient cases to date Currently conducting patient cases in 9 medical centers across the country including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX, Mayo Clinic Florida Campus and the University of Pennsylvania BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it increased the patient case goal from 1000 to at least 1500 procedures by ... |
BSGM Price Returns
| 1-mo | 9.20% |
| 3-mo | -19.47% |
| 6-mo | -17.49% |
| 1-year | -64.95% |
| 3-year | -33.09% |
| 5-year | -5.03% |
| YTD | -5.64% |
| 2020 | -34.12% |
| 2019 | 38.64% |
| 2018 | 18.60% |
| 2017 | 11.64% |
| 2016 | -0.39% |
Loading social stream, please wait...